title: Role of platelet-derived chemokines (RANTES and ENA-78) after stem cell transplantation.
abstract: Stem cell transplantation (SCT) is being used for hematopoietic reconstitution following high-dose chemotherapy for malignancy. Some patients seem to have an imbalance of the immune response after SCT and cytokines are known to regulate this response. Recently, platelets have been shown to contain members of the chemokine family, suggesting a role of platelets as inflammatory cells. We measured and compared levels of platelet activation markers, chemokines, and soluble factors in patients undergoing SCT. IL-8 and GROalpha exhibited a significant elevation in the early phase (1 or 2 weeks) after SCT; this trend was marked after autologous SCT. Furthermore, these levels significantly and positively correlated with the change in G-CSF. In contrast, ENA-78 exhibited a significant elevation in the later phase (3 or 4 weeks) after SCT. In addition, its level negatively correlated with the change in G-CSF. Soluble CD40 ligand and platelet-derived microparticles significantly increased after both auto- and allo-SCT. In addition, ENA-78 positively correlated with the level of platelet-derived microparticles. The increase of RANTES seems to be related to platelet activation, since RANTES was in the dynamic phase similar to soluble CD40 ligand and platelet-derived microparticles. RANTES exhibited changes similar to IL-6, TNFalpha, and soluble IL-2 receptors, which are GVHD markers. Thus, the platelet-derived chemokines ENA-78 and RANTES exhibited particular changes after SCT. Our results suggest that ENA-78 play a role in hematopoietic conditions in which G-CSF is not involved, and RANTES generation after allo-SCT relates to GVHD.
authors.affiliation: Division of Hematology, Kisiwada City Hospital, 1001, Kishiwada, Osaka 596-8501, Japan. shosaku-n@mbp.ocn.ne.jp
authors.forename: Shosaku
authors.initials: S
authors.lastname: Nomura
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Ishii
authors.forename: Shigenori
authors.initials: S
authors.lastname: Kanazawa
authors.forename: Norihito
authors.initials: N
authors.lastname: Inami
authors.forename: Yuri
authors.initials: Y
authors.lastname: Kamitsuji
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Uoshima
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ishida
authors.forename: Takao
authors.initials: T
authors.lastname: Yoshihara
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kitayama
authors.forename: Kunio
authors.initials: K
authors.lastname: Hayashi
mesh_terms: D001792:Blood Platelets / Q000276:immunology; D018946:Chemokine CCL5 / Q000097:blood*; D054365:Chemokine CXCL5; D018925:Chemokines / Q000097:blood; D019743:Chemokines, CXC / Q000097:blood*; D016207:Cytokines / Q000097:blood; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D016179:Granulocyte Colony-Stimulating Factor / Q000097:blood; D006410:Hematopoiesis; D006801:Humans; D008297:Male; D033581:Stem Cell Transplantation / Q000009:adverse effects; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: C486263:CXCL5 protein, human; D018946:Chemokine CCL5; D054365:Chemokine CXCL5; D018925:Chemokines; D019743:Chemokines, CXC; D016207:Cytokines; D016179:Granulocyte Colony-Stimulating Factor